ÂÜÀòÂÒÂ×

Anna-Kaisa Lehtivarjo has extensive work experience in quality assurance and regulatory affairs in the pharmaceutical industry. Anna-Kaisa is currently the Head of Quality at Resolution Therapeutics since February 2023. Prior to that, they worked as a QA/RA Specialist Consultant at Kasve Ltd from February 2022 to February 2023, where they supported ATMP companies in regulatory strategy, quality system development, and conducted audits.

Anna-Kaisa also worked at FinVector Oy, where they held various roles. Anna-Kaisa served as the Quality Unit Director from September 2020 to January 2022, overseeing quality activities and participating in decision-making processes. Anna-Kaisa also worked as a Qualified Person (QP) from August 2017 to January 2022, reviewing and releasing gene therapy drug product batches for clinical trials. Additionally, they were a Regulatory Affairs Manager (CMC) from November 2019 to September 2020 and QA Manager from November 2017 to September 2020, responsible for managing quality systems and conducting audits.

Earlier in their career, Anna-Kaisa worked at FinVector Vision Therapies Oy as a QA Manager from June 2014 to November 2017, overseeing quality activities and managing auditors. Anna-Kaisa also held the role of QA Scientist/Project Manager from September 2008 to June 2014.

Before entering the pharmaceutical industry, Anna-Kaisa worked as a Research Scientist at the University of Kuopio from May 2007 to September 2008.

From 2002 to 2007, Anna-Kaisa Lehtivarjo attended the University of Eastern Finland, where they obtained their MSc in Applied Biotechnology.